Research Article

Practice patterns and outcomes of repository corticotropin injection (Acthar® Gel) use in childhood nephrotic syndrome: A study of the North American Pediatric Renal Trials and collaborative studies and the Pediatric Nephrology Research Consortium

Mohammed K Faizan*, Courtney McCracken, Kenneth Lieberman, Traci Leong and Mark R Benfield

Published: 07/23/2021 | Volume 5 - Issue 2 | Pages: 067-076


Objective: We set up a U.S. registry to examine prescription patterns and patient outcomes of repository corticotropin injection (Acthar® Gel) for childhood nephrotic syndrome.

Methods: 18 participating U.S. pediatric centers performed retrospective review and prospective observation of patients < 21 years old with nephrotic syndrome treated with Acthar Gel. We captured baseline characteristics, drug regimen and duration, and disease response following treatment.

Results: 46 patients, enrolled from 2015 to 2020 were included. 27 (58.7%) were male. 18 patients (39.1%) had a diagnosis of minimal change followed by focal segmental glomerulosclerosis in 16 patients (34.7%). Median age at start of treatment was 12.5 years (IQR 8.5-17.4) compared to 5.3 years at diagnosis (IQR 2.7-10.5 years). 52% were resistant to corticosteroids. The most common Acthar Gel regimen was 80IU twice a week with a median duration of 199 days (IQR 88-365). Among 37 patients with active disease, 18 (49%) were able to achieve partial or complete remission, though all patients that had a positive response were on other immunosuppressants concomitantly.

Conclusion: We report the findings of the largest registry cohort of pediatric patients in the U.S. treated with Acthar Gel for clinically challenging cases of nephrotic syndrome. Acthar Gel was successful in inducing remission in approximately half of the patients with active disease at time of treatment. No predictors of response with respect to demographic data, age at start of Acthar Gel therapy, etiology of nephrotic syndrome, presence or absence of comorbidities, or steroid responsiveness was noted.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001077 Cite this Article


  1. Greenbaum LA, Benndorf R, Smoyer WE. Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol. 2012; 8: 445-458. PubMed:
  2. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes: Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28: 415-426. PubMed:
  3. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003; 362: 629-639. PubMed:
  4. Lieberman KV, Pavlova-Wolf A. Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance. J Nephrol. 2017; 30: 35-44. PubMed:
  5. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2011; 8: 122-128. PubMed:
  6. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant. 2004; 19: 1305-1307. PubMed:
  7. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999; 56: 1534-1543. PubMed:
  8. Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011; 5: 147-153. PubMed:
  9. Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, et al. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016; 17: 37. PubMed:
  10. Mallinckrodt Pharmaceuticals. Acthar Gel. 2019.
  11. Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, et al. Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial. Clin J Am Soc Nephrol. 2018; 13: 1859-1865. PubMed:
  12. Wang CS, Greenbaum LA. Nephrotic Syndrome. Pediatr Clin North Am. 2019; 66: 73-85. PubMed:
  13. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013; 8: 2072-2081. PubMed:
  14. Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014; 29: 1570-1577. PubMed:
  15. Hartung DM, Johnston K, Deodhar A, Bourdette DN, Cohen DM. Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence? Am J Kidney Dis. 2019; 74: 256-262. PubMed:
  16. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20: 629-637. PubMed: